Provenge Coverage With Data Collection Suggested By MEDCAC Members
Executive Summary
The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.
You may also be interested in...
Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors
Agency decides against requiring coverage with evidence development for off-label uses.
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.